137 related articles for article (PubMed ID: 38052308)
1. Repurposing of pexidartinib for microglia depletion and renewal.
Weyer MP; Strehle J; Schäfer MKE; Tegeder I
Pharmacol Ther; 2024 Jan; 253():108565. PubMed ID: 38052308
[TBL] [Abstract][Full Text] [Related]
2. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
[TBL] [Abstract][Full Text] [Related]
3. Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
Tap WD; Singh AS; Anthony SP; Sterba M; Zhang C; Healey JH; Chmielowski B; Cohn AL; Shapiro GI; Keedy VL; Wainberg ZA; Puzanov I; Cote GM; Wagner AJ; Braiteh F; Sherman E; Hsu HH; Peterfy C; Gelhorn HL; Ye X; Severson P; West BL; Lin PS; Tong-Starksen S
Clin Cancer Res; 2022 Jan; 28(2):298-307. PubMed ID: 34716196
[TBL] [Abstract][Full Text] [Related]
4. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
[TBL] [Abstract][Full Text] [Related]
5. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
Alsayadi YMMA; Chawla PA
Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
[TBL] [Abstract][Full Text] [Related]
6. A limited capacity for microglial repopulation in the adult brain.
Najafi AR; Crapser J; Jiang S; Ng W; Mortazavi A; West BL; Green KN
Glia; 2018 Nov; 66(11):2385-2396. PubMed ID: 30370589
[TBL] [Abstract][Full Text] [Related]
7. Concentration-dependent effects of CSF1R inhibitors on oligodendrocyte progenitor cells ex vivo and in vivo.
Liu Y; Given KS; Dickson EL; Owens GP; Macklin WB; Bennett JL
Exp Neurol; 2019 Aug; 318():32-41. PubMed ID: 31029597
[TBL] [Abstract][Full Text] [Related]
8. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
Palmerini E; Longhi A; Donati DM; Staals EL
Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
[TBL] [Abstract][Full Text] [Related]
9. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
Baldi GG; Gronchi A; Stacchiotti S
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
[TBL] [Abstract][Full Text] [Related]
10. Early posttraumatic CSF1R inhibition via PLX3397 leads to time- and sex-dependent effects on inflammation and neuronal maintenance after traumatic brain injury in mice.
Wang Y; Wernersbach I; Strehle J; Li S; Appel D; Klein M; Ritter K; Hummel R; Tegeder I; Schäfer MKE
Brain Behav Immun; 2022 Nov; 106():49-66. PubMed ID: 35933030
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of CSF1R and KIT With Pexidartinib Reduces Inflammatory Signaling and Cell Viability in Endometriosis.
Dunn TN; Cope DI; Tang S; Sirupangi T; Parks SE; Liao Z; Yuan F; Creighton CJ; Masand RP; Alpuing Radilla L; Guan X; Detti L; Monsivais D; Matzuk MM
Endocrinology; 2024 Feb; 165(4):. PubMed ID: 38227801
[TBL] [Abstract][Full Text] [Related]
12. Distinguishing the effects of systemic CSF1R inhibition by PLX3397 on microglia and peripheral immune cells.
Okojie AK; Uweru JO; Coburn MA; Li S; Cao-Dao VD; Eyo UB
J Neuroinflammation; 2023 Oct; 20(1):242. PubMed ID: 37865779
[TBL] [Abstract][Full Text] [Related]
13. Microglial depletion and repopulation in brain slice culture normalizes sensitized proinflammatory signaling.
Coleman LG; Zou J; Crews FT
J Neuroinflammation; 2020 Jan; 17(1):27. PubMed ID: 31954398
[TBL] [Abstract][Full Text] [Related]
14. Depletion of microglia exacerbates postischemic inflammation and brain injury.
Jin WN; Shi SX; Li Z; Li M; Wood K; Gonzales RJ; Liu Q
J Cereb Blood Flow Metab; 2017 Jun; 37(6):2224-2236. PubMed ID: 28273719
[TBL] [Abstract][Full Text] [Related]
15. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
Butowski N; Colman H; De Groot JF; Omuro AM; Nayak L; Wen PY; Cloughesy TF; Marimuthu A; Haidar S; Perry A; Huse J; Phillips J; West BL; Nolop KB; Hsu HH; Ligon KL; Molinaro AM; Prados M
Neuro Oncol; 2016 Apr; 18(4):557-64. PubMed ID: 26449250
[TBL] [Abstract][Full Text] [Related]
16. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor.
Gelderblom H; de Sande MV
Future Oncol; 2020 Oct; 16(29):2345-2356. PubMed ID: 32700568
[TBL] [Abstract][Full Text] [Related]
17. Pexidartinib: First Approval.
Lamb YN
Drugs; 2019 Nov; 79(16):1805-1812. PubMed ID: 31602563
[TBL] [Abstract][Full Text] [Related]
18. CSF1R inhibitor PLX3397 depletes microglia in Mongolian gerbil Meriones unguiculatus, but not in syrian hamster Mesocricetus auratus.
Sato RY; Zhang Y; Kotake KT; Onishi H; Ito S; Norimoto H; Zhou Z
J Pharmacol Sci; 2024 Jun; 155(2):29-34. PubMed ID: 38677783
[TBL] [Abstract][Full Text] [Related]
19. Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis.
Thongchot S; Duangkaew S; Yotchai W; Maungsomboon S; Phimolsarnti R; Asavamongkolkul A; Thuwajit P; Thuwajit C; Chandhanayingyong C
Hum Cell; 2023 Jan; 36(1):456-467. PubMed ID: 36456782
[TBL] [Abstract][Full Text] [Related]
20. Underestimated Peripheral Effects Following Pharmacological and Conditional Genetic Microglial Depletion.
Han J; Fan Y; Zhou K; Zhu K; Blomgren K; Lund H; Zhang XM; Harris RA
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33203068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]